December 20, 2017, Vancouver, British Columbia – Vodis Pharmaceuticals Inc. (CSE:VP, FWB:1JV1) (“Vodis” or the “Company”) announces the appointment of John Bean as a director of the Company effective immediately.
Experienced Cannabis Sector CFO Provides Financial Leadership and Further Strengthens Corporate Governance
Mr. Bean, who will sit as an independent Director, has financial management, capital markets and corporate governance experience in the medical cannabis industries. He is a CPA (BC), CA.
Mr. Bean was the CFO of Aurora Cannabis Inc. (TSX:ACB), a licensed producer of medical cannabis, during its first two years as a public company, when it obtained its licence to grow, became licence to sell, and then received customer revenue.
Mr. Bean has served on the boards of Prescient Mining Corp., which became Aurora Cannabis Inc.; General Fusion Inc.; SyncWave Energy Inc.; TAP Ventures, Inc.; RSI International, BC Technologies Industry Association; Accenture’s CSTaR (Center for Strategic Technology Research); and Bobolink Daycare Society for Deaf Children.
"John is a valuable addition to Vodis’ Board, bringing significant financial and capital markets experience, as we enter a pivotal period in our corporate development," said Ivan Miliovski, CEO. "His wise counsel will serve our shareholders well, as we execute on our strategic plans.”
"I am delighted to join the Vodis team, and excited to support the Company's rapid growth" said Mr. Bean.
In connection with the above appointment, the Company has granted John Bean an aggregate of 200,000 stock options exercisable at $0.485 per common share for a period of five years expiring on December 20, 2022, subject to all requisite regulatory approvals.
About Vodis Pharmaceuticals Inc.
Vodis is one of North America’s foremost brand names in the medical and recreational marijuana business with operations in both the United States and Canada. Its master grow teams have consistently won or placed at each Canadian competition they have entered with their “VIP” brand. The Company, with facilities in British Columbia and Washington State, is also actively looking into expansion opportunities in other countries and throughout the United States.
While Vodis and its subsidiaries cannot have any interest whatsoever in any proceeds as a result of production, processing or retail activities in the United States, it can license its brand, production and consulting services to approved Washington State license holders to ensure that all products produced under the Vodis Pharmaceuticals program and/or associated under the VIP brand meet or exceed Vodis-brand quality standards.
For further information please contact:
Ivan Miliovski, Chief Executive Officer
Vodis Pharmaceuticals Inc.
Vodis Pharmaceuticals Inc.
8788 River Road
Delta, BC V4G 1B4
The Canadian Securities Exchange has neither approved nor disapproved the contents of this news release and accepts no responsibility for the adequacy or accuracy hereof.
- Page 1 of 73